# A Study for Treatment of Pain in Patients With Diabetic Neuropathy.

> **NCT00785577** · PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 273 (actual)

## Conditions studied

- Diabetic Neuropathy, Painful

## Interventions

- **DRUG:** Placebo
- **DRUG:** Pregabalin
- **DRUG:** LY545694 21 mg
- **DRUG:** LY545694 49 mg
- **DRUG:** LY545694 105 mg

## Key facts

- **NCT ID:** NCT00785577
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-11
- **Primary completion:** 2010-05
- **Final completion:** 2010-06
- **Target enrollment:** 273 (ACTUAL)
- **Last updated:** 2012-05-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00785577

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00785577, "A Study for Treatment of Pain in Patients With Diabetic Neuropathy.". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00785577. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*